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Pemphigus are blistering autoimmune diseases related with
genetic and environmental factors. Here we describe HLA geno-
typing in pemphigus patients. First, we review the HLA class I/II
data on pemphigus reported in Brazilian samples and then present
the HLA class I (-A, -B, -C) and class II (-DRB1, -DQA1, -DQB1) alleles
related to susceptibility/resistance to pemphigus by comparing 86
patients with pemphigus foliaceus, 83 patients with pemphigus
vulgaris, and 1592 controls from the northeastern region of the
state of São Paulo, Southeastern Brazil. The data presented here are
related to the manuscript “Differential HLA class I and class II
associations in Pemphigus Foliaceus and Pemphigus Vulgaris
patients from a prevalent Southeastern Brazilian region” Brochado
et al. (2016) [1].
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ject areaDermatology, Immunology, and Geneticsype of data Tables
ow data was
acquiredThe reviewing of the literature was made by using the Pubmed, and the HLA
typing by using PCR-SSOP methodata format Analyzed
xperimental
factorsDNA blood samples from pemphigus patients and controlsxperimental
featuresHLA class I and II typing was performed using commercial kits (One Lambda Inc.,
Canoga Park, CA)ata source
locationNortheastern region of the state of São Paulo, Southeastern Brazilata accessibility Data is with this articleDValue of the data The literature review regarding HLA class I/II data on pemphigus is shown in tables comparing
different studied Brazilian populations.
 The northeastern region of the state of São Paulo, Southeastern Brazil, is prevalent for both clinical
forms of pemphigus–pemphigus foliaceus and pemphigus vulgaris, enabling a comparative study.
 HLA class I/II frequencies are detailed comparing pemphigus foliaceus and pemphigus vulgaris
patients from the same endemic region.1. Data
Tables 1 and 2 describe the HLA class I and II data related to susceptibility/resistance to pemphigus
foliaceus and pemphigus vulgaris in reviewed Brazilian reports. Tables 3–8 show the HLA class I (-A,
-B, -C) and class II (-DRB1, -DQA1, -DQB1) proﬁle performed in pemphigus foliaceus and pemphigus
vulgaris patients from Southeastern Brazil.2. Experimental design, materials, and methods
A summary of Brazilian data regarding associations between HLA and pemphigus was obtained in
PubMed. A hundred and sixty-nine patients followed up at the University Hospital of the Ribeirão
Preto Medical School of the University of São Paulo, Brazil, were evaluated. Eighty-six and 83 patients
exhibited PF and PV, respectively. The control group consisted of 1592 healthy individuals living in the
northeastern region of the state of São Paulo, Southeastern Brazil. HLA class I and II typing was
performed at low/high resolution by using commercial kits, according to the manufacturer's protocol
(One Lambda Inc., Canoga Park, CA). The allelic frequencies of the HLA class I and II genes were
estimated by direct counting. Comparison of allele frequency among the groups was performed by
using Fisher's exact test or the Chi-square test. Signiﬁcant P-values were corrected by the number of
alleles tested for each locus. The relative risk (RR) 95% was estimated. Statistical analysis was per-
formed with SAS 9.3 (SAS Institute Inc, EUA) and Epi InfoTM 7.0 (CDC, USA) software. Values Pr0.05
were considered signiﬁcant. All the participants provided an informed written consent to participate
in this study. The local Ethics Committee (#12248/2010) approved this study.
Table 1
Brazilian reports on pemphigus foliaceus associated alleles.
References Brazilian population Patients/
Controls
DRB1* P-value, RR or OR DQA1* P-value, RR DQB1* P-value, RR or OR
Susceptibility – Pemphigus Foliaceus
PetzL-Erler et al.
(1989) [2]








State of São Paulo and Brasília
city (Federal District)
38/50 01:02 Pc¼0.002, RR¼7.3
Cerna et al. (1993)
[4]
Xavante Indians – Central Brazil 10/74 04:04 Pc¼0.03, RR¼9.6
Moraes et al.
(1997) [5]
Terena Indians – state of Mato
Grosso do Sul
20/66 04:04 Pc¼0.022, OR¼6.1 03:02 Pc¼0.04, OR¼5.2
Pavoni et al.
(2003) [6]
State of Mato Grosso do Sul and
Paraná













Northeastern region of the state
of São Paulo
86/1592 01:01 Pc¼0.0001, RR¼2.18 01 Pc¼0.02, RR¼1.41 05:01 Pc¼2.51010,
RR¼2.95
01:02 Pc¼5.4e10, RR¼6.06 01:02 Pc¼3.6103,
RR¼2.3
03 Pc¼0.01, RR¼1.78
Protection – Pemphigus Foliaceus
Petzl-Erler et al.
(1989) [2]







State of São Paulo and Brasília
city (Federal District)


































Northeastern region of the state
of São Paulo
11:01 Pc¼0.027, RR¼0.07 02:01 Pc¼0.03, RR¼0.34 03:01 Pc¼0.0002; RR¼0.39
13:01 Pc¼0.027, OR¼0.20 05 Pc¼1.08105,
RR¼0.28
06:03 Pc¼0.023, RR¼0.2















Brazilian reports on pemphigus vulgaris associated alleles.
References Brazilian population Patients/
Controls
DRB1* P-value, OR or RR DQA1* P-value, OR DQB1* P-value, RR
Susceptibility – Pemphigus Vulgaris
Weber et al. (2011)
[7]
Southeastern region of the






Northeastern region of the
state of São Paulo
82/1592 04:02 Pc¼5.41010,
RR¼12.54
03 Pc¼0.01, OR¼2.04 03:02 Pc¼2.51010, RR¼
2.95






Protection – Pemphigus Vulgaris
Brochado et al.
(2016) [1]
Northeastern region of the
state of São Paulo
82/1592 07:01 Pc¼0.027, RR¼0.28 06:02 Pc¼0.0075, RR¼0.19























n (%) n (%) n (%)
01 291 (9.14) 12 (7.23) 21 (12.65)
02 1028 (32.29) 31 (18.67)a 38 (22.89)
03 277 (8.70) 18 (10.84) 9 (5.42)
04 1 (0.03) 0 0
06 2 (0.06) 0 0
11 126 (3.96) 16 (9.64)b 11 (6.63)
23 127 (3.99) 8 (4.82) 4 (2.41)
24 324 (10.18) 16 (9.64) 18 (10.84)
25 38 (1.19) 2 (1.20) 4 (2.41)
26 86 (2.70) 5 (3.01) 13 (7.83)c
29 114 (3.58) 4 (2.41) 2 (1.20)
30 163 (5.12) 14 (8.43) 11 (6.63)
31 149 (4.68) 6 (3.61) 4 (2.41)
32 95 (2.98) 3 (1.81) 5 (3.01)
33 73 (2.29) 11 (6.63)d 6 (3.61)
34 18 (0.57) 3 (1.81) 1 (0.60)
36 13 (0.41) 1 (0.60) 1 (0.60)
66 17 (0.53) 3 (1.81) 2 (1.20)
68 205 (6.44) 8 (4.82) 13 (7.83)
69 1 (0.03) 0 0
74 34 (1.07) 5 (3.01) 1 (0.60)
80 2 (0.06) 0 2 (1.20)
RR¼Relative Risk, CI¼conﬁdence interval.
a P¼2.104, RR¼0.57, 95% CI¼0.42–0.80.
b P¼0.04, RR¼2.43, 95% CI¼1.5–4.0.
c P¼0.02, RR¼2.89, 95% CI¼1.65–5.08.























n (%) n (%) n (%)
07 229 (7.19) 13 (7.83) 5 (3.05)
08 111 (3.49) 8 (4.82) 2 (1.22)
13 35 (1.10) 3 (1.81) 4 (2.44)
14 161 (5.06) 23 (13.86)a 4 (2.44)
15 379 (11.90) 12 (7.23) 5 (3.05)b
18 185 (5.81) 3 (1.81) 5 (3.05)
27 45 (1.41) 3 (1.81) 4 (2.44)
35 444 (13.94) 19 (11.45) 26 (15.85)
37 25 (0.79) 3 (1.81) 2 (1.22)
38 60 (1.88) 2 (1.20) 12 (7.32)c
39 113 (3.55) 11 (6.63) 9 (5.49)
40 124 (3.89) 10 (6.02) 8 (4.88)
41 31 (0.97) 1 (0.60) 1 (0.61)
42 33 (1.04) 2 (1.20) 3 (1.83)
44 333 (10.46) 14 (8.43) 23 (14.02)
45 45 (1.41) 4 (2.41) 3 (1.83)
47 5 (0.16) 0 0
48 21 (0.66) 3 (1.81) 0
49 68 (2.14) 1 (0.60) 4 (2.44)
50 75 (2.36) 4 (2.41) 4 (2.44)
51 330 (10.36) 8 (4.82) 13 (7.93)
52 49 (1.54) 3 (1.81) 2 (1.22)
53 55 (1.73) 3 (1.81) 8 (4.88)
55 33 (1.04) 2 (1.20) 4 (2.44)
56 4 (0.13) 1 (0.60) 0
57 92 (2.89) 6 (3.61) 10 (6.10)
58 86 (2.70) 4 (2.41) 1 (0.61)
73 4 (0.13) 0 1 (0.61)
81 8 (0.25) 0 1 (0.61)
82 1 (0.03) 0 0
RR¼Relative Risk, CI¼conﬁdence interval.
a P¼6104, RR¼2.74, 95% CI¼1.82–4.12.
b P¼0.003, RR¼0.26, 95% CI¼0.10–0.61.
c P¼0.003, RR¼3.88, 95% CI¼2.13–7.07.
Table 5









n (%) n (%) n (%)
01 55 (2.11) 3 (1.81) 5 (3.05)
02 176 (6.74) 15 (9.04) 10 (6.10)
03 278 (10.65) 14 (8.43) 11 (6.71)
04 475 (18.20) 27 (16.27) 32 (19.51)
05 144 (5.52) 8 (4.82) 13 (7.93)
06 212 (8.12) 14 (8.43) 14 (8.54)
07 578 (22.15) 33 (19.88) 24 (14.63)
08 135 (5.17) 17 (10.24) 5 (3.05)
12 155 (5.94) 10 (6.02) 21 (12.80)a
14 79 (3.03) 0 4 (2.44)
15 111 (4.25) 13 (7.83) 11 (6.71)
16 144 (5.52) 7 (4.22) 10 (6.10)
17 52 (1.99) 3 (1.81) 4 (2.44)
18 16 (0.61) 2 (1.20) 0
RR¼Relative Risk, CI¼conﬁdence interval
a P¼0.01, RR¼2.16, 95% CI¼1.40–3.30.
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Table 6
Allelic HLA-DRB1 frequencies among Brazilian pemphigus foliaceus and pemphigus vulgaris patients as compared to controls.
HLA-DRB1n Controls (n¼1592) Pemphigus foliaceus (n¼86) Pemphigus vulgaris (n¼82)
n (%) n (%) n (%)
01:01 150 (4.7) 23 (13.4)a 6 (3.7)
01:02 113 (3.6) 37 (21.5)b 3 (1.8)
01:03 22 (0.7) 1 (0.6) 0
03:01 247 (7.8) 10 (5.8) 4 (2.4)
03:02 25 (0.8) 3 (1.7) 2 (1.2)
04 0 2 (1.2) 0
04:01 79 (2.5) 3 (1.7) 2 (1.2)
04:02 65 (2.0) 4 (2.3) 42 (25.6)c
04:03 38 (1.2) 2 (1.2) 4 (2.4)
04:04 88 (2.8) 10 (5.8) 5 (3.1)
04:05 63 (2.0) 4 (2.3) 1 (0.6)
04:06 8 (0.3) 1 (0.6) 0
04:07 27 (0.9) 1 (0.6) 0
04:08 21 (0.7) 2 (1.2) 0
04:10 2 (0.1) 0 0
04:11 54 (1.7) 7 (4.1) 2 (1.2)
07:01 342 (10.7) 6 (3.5) 5 (3.1)d
08:01 71 (2.2) 0 2 (1.2)
08:02 34 (1.1) 3 (1.7) 1 (0.6)
08:03 10 (0.3) 0 0
08:04 42 (1.3) 2 (1.2) 13 (7.9)e
08:07 25 (0.8) 1 (0.6) 0
09:01 41 (1.3) 4 (2.3) 0
10:01 43 (1.4) 1 (0.6) 1 (0.6)
11 0 0 1 (0.6)
11:01 258 (8.1) 1 (0.6)f 9 (5.5)
11:02 72 (2.3) 1 (0.6) 5 (3.1)
11:03 31 (1.0) 0 0
11:04 138 (4.3) 1 (0.6) 4 (2.4)
11:06 1 (0.03) 0 0
11:13 1 (0.03) 0 0
11:18 1 (0.03) 0 0
12:01 35 (1.1) 3 (1.7) 1 (0.6)
12:02 3 (0.1) 0 0
13:01 274 (8.6) 3 (1.7)g 4 (2.4)
13:02 158 (5.0) 2 (1.2) 3 (1.8)
13:03 55 (1.7) 0 2 (1.2)
13:05 2 (0.1) 0 0
13:06 1 (0.03) 0 0
13:21 1 (0.03) 0 0
13:23 1 (0.03) 0 0
13:31 1 (0.03) 0 0
14:01 70 (2.2) 0 25 (15.2)h
14:02 35 (1.1) 1 (0.6) 3 (1.8)
14:04 7 (0.2) 2 (1.2) 6 (3.7)i
14:06 7 (0.2) 1 (0.6) 0
14:09 1 (0.03) 0 0
15:01 194 (6.1) 12 (7.0) 2 (1.2)
15:02 24 (0.8) 0 2 (1.2)
15:03 79 (2.5) 5 (2.9) 0
15:04 1 (0.03) 0 0
15:11 1 (0.03) 0 0
16:01 66 (2.1) 10 (5.8) 2 (1.2)
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Table 6 (continued )
HLA-DRB1n Controls (n¼1592) Pemphigus foliaceus (n¼86) Pemphigus vulgaris (n¼82)
n (%) n (%) n (%)
16:02 56 (1.8) 3 (1.7) 2 (1.2)
RR¼relative risk, CI¼conﬁdence interval.
a P¼1104, RR¼2.83, 95% CI¼1.88–4.28.
b P¼51010, RR¼6.06, 95% CI¼4.32–8.49.
c P¼5.41010, RR¼12.54, 95% CI¼8.79–17.88.
d P¼0.027, RR¼0.28, 95% CI¼0.12–0.67.
e P¼5.4105, RR¼6.0, 95% CI¼3.29–10.97.
f P¼0.027, RR¼0.07, 95% CI¼0.01–0.50.
g P¼0.027, RR¼0.20, 95% CI¼0.06–0.62.
h P¼5.41010, RR¼7.21, 95% CI¼4.72–10.99.
i P¼5.4104, RR¼16.64, 95% CI¼5.65–48.95.
Table 7
Allelic HLA-DQA1 frequencies among Brazilian pemphigus foliaceus and pemphigus vulgaris patients as compared to controls.
HLA-DQA1n Controls (n¼1312) Pemphigus foliaceus (n¼86) Pemphigus vulgaris (n¼82)
n (%) n (%) n (%)
01 760 (29.0) 70 (40.7)a 47 (28.7)
01:02 155 (5.9) 24 (14.0)b 8 (4.9)
01:03 130 (5.0) 3 (1.7) 4 (2.4)
01:06 3 (0.11) 0 0
01:07 4 (0.15) 2 (1.2) 0
01:09 1 (0.04) 0 0
02:01 267 (10.2) 6 (3.5)c 6 (3.7)
03 318 (12.1) 37 (21.5)d 36 (22.0)e
03:01 88 (3.4) 5 (2.9) 20 (12.2)f
04 1 (0.04) 0 0
04:01 146 (5.6) 7 (4.1) 10 (6.1)
04:03 2 (0.1) 0 0
04:04 2 (0.1) 0 0
05 499 (19.0) 9 (5.2)g 27 (16.5)
05:01 201 (7.7) 9 (5.2) 5 (3.1)
05:02 2 (0.1) 0 0
05:10 33 (1.3) 0 1 (0.6)
06:01 12 (0.5) 0 0
RR¼relative risk, CI¼conﬁdence interval.
a P¼0.02, RR¼1.41, 95% CI¼1.16–1.69.
b P¼3.6103, RR¼2.36, 95% CI¼1.58–3.52.
c P¼0.03, RR¼0.34, 95% CI¼0.15–0.75.
d P¼0.01, RR¼1.78, 95% CI¼1.31–2.40.
e P¼0.01, RR¼1.81, 95% CI¼1.33–2.46.
f P¼4104, RR¼3.64, 95% CI¼2.29–5.75.
g P¼1.08105, RR¼0.28, 95% CI¼0.14–0.52.
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Table 8









n (%) n (%) n (%)
02:01 233 (8.26) 9 (5.23) 4 (2.44)
02:02 260 (9.21) 6 (3.49) 5 (3.05)
03 2 (0.07) 0 1 (0.61)
03:01 626 (22.18) 15 (8.72)a 30 (18.29)
03:02 297 (10.52) 27 (15.70) 51 (31.10)b
03:03 75 (2.66) 4 (2.33) 1 (0.61)
03:04 3 (0.11) 0 0
03:05 1 (0.04) 0 1 (0.61)
03:19 13 (0.46) 0 2 (1.22)
04 0 1 (0.58) 1 (0.61)
04:01 3 (0.11) 0 0
04:02 170 (6.02) 12 (6.98) 9 (5.49)
05 0 7 (4.07) 22 (13.41)
05:01 328 (11.62) 59 (34.30)c 10 (6.10)
05:02 91 (3.22) 11 (6.40) 3 (1.83)
05:03 69 (2.45) 1 (0.58) 11 (6.71)d
05:05 1 (0.04) 0 0
06 8 (0.28) 0 0
06:01 19 (0.67) 0 3 (1.83)
06:02 263 (9.32) 16 (9.30) 3 (1.83)e
06:03 226 (8.01) 3 (1.74)f 4 (2.44)
06:04 99 (3.51) 1 (0.58) 3 (1.83)
06:09 29 (1.03) 0 0
06:11 5 (0.18) 0 0
16:02 1 (0.04) 0 0
RR¼relative risk, CI¼conﬁdence interval.
a P¼2104, RR¼0.39, 95% CI¼0.24–0.64.
b P¼2.51010, RR¼2.95, 95% CI¼2.3–3.80.
c P¼2.51010, RR¼2.95, 95% CI¼2.34–3.71.
d P¼0.02, RR¼2.74, 95% CI¼1.49–5.08.
e P¼7.5103, RR¼0.19, 95% CI¼0.06–0.60.
f P¼0.02, RR¼0.22, 95% CI¼0.07–0.67.
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